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• The MTHFR 677TT genotype is associated with a 24-87% increased risk of 23 
hypertension 24 
• Riboflavin (the precursor for the MTHFR cofactor, FAD), lowers BP in TT adults  25 
• Perturbed one-carbon metabolism may influence the BP phenotype linked with TT 26 
genotype 27 
• SAM concentrations and SAM:SAH ratio were lower in individuals with the TT 28 
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• In the TT genotype group, SAM and cystathionine increased in response to riboflavin  30 
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Abstract  44 
Homozygosity for the C677T polymorphism in MTHFR (TT genotype) is associated with a 45 
24-87% increased risk of hypertension. Blood pressure (BP) lowering was previously 46 
reported in adults with the TT genotype, in response to supplementation with the MTHFR 47 
cofactor, riboflavin. Whether the BP phenotype associated with the polymorphism is related 48 
to perturbed one-carbon metabolism is unknown. This study investigated one carbon 49 
metabolites and their responsiveness to riboflavin in adults with the TT genotype. Plasma 50 
samples from adults (n 115) screened for the MTHFR genotype, who previously participated 51 
in RCTs to lower BP, were analysed for methionine, S-adenosylmethionine (SAM), S-52 
adenosylhomocysteine (SAH), betaine, choline and cystathionine by liquid chromatography 53 
tandem mass spectrometry (LC-MS/MS). The one-carbon metabolite response to riboflavin 54 
(1.6 mg/d; n 24) or placebo (n 23) for 16 weeks in adults with the TT genotype was also 55 
investigated. Plasma SAM (74.7 ± 21.0 vs 85.2 ± 22.6 nmol/L, P=0.013) and SAM:SAH ratio 56 
(1.66 ± 0.55 vs 1.85 ± 0.51, P=0.043) were lower and plasma homocysteine was higher 57 
(P=0.043) in TT, compared to CC individuals. In response to riboflavin, SAM (P=0.008) and 58 
cystathionine (P=0.045) concentrations increased, with no responses in other one-carbon 59 
metabolites. These findings confirm perturbed one-carbon metabolism in individuals with the 60 
MTHFR 677TT genotype, and for the first time demonstrate that SAM, and cystathionine, 61 
increase in response to riboflavin supplementation in this genotype group. The genotype-62 
specific, one-carbon metabolite responses to riboflavin intervention observed could offer 63 




1.0 Introduction 65 
Hypertension is a major modifiable risk factor for st oke and cardiovascular disease (CVD),  66 
and a leading cause of premature mortality worldwide, responsible for over 10 million deaths 67 
annually [1]. The pathophysiology of hypertension is complex, involving the interaction of 68 
genetics, environmental factors and physiological mechanisms [2]. Genome wide association 69 
studies (GWAS) have linked a number of genetic lociwith hypertension [3,4], including a 70 
region near the gene encoding the folate metabolising enzyme, methylenetetrahydrofolate 71 
reductase (MTHFR). The common MTHFR C677T polymorphism produces an enzyme with 72 
reduced activity [5] owing to lowered affinity for its riboflavin cofactor, (flavin adenine 73 
dinucleotide, FAD) [6]. The homozygous MTHFR 677TT genotype affects 2-32% of 74 
populations worldwide [7] and meta-analyses have estimated that the variant TT genotype is 75 
associated with 24-87% increased risk of hypertension and increased risk for CVD by up to 76 
40% [8]. Previous studies conducted at this Centre have demonstrated that BP is highly 77 
responsive to riboflavin supplementation, with evidnce that systolic BP can be lowered by 78 
between 6 to 14 mmHg in individuals with the TT genotype [9–11]. This gene-nutrient 79 
interaction thus offers a novel, nutritional approach for BP management among adults with 80 
the C677T variant in MTHFR, although the underlying mechanism remains unexplained. It is 81 
possible the phenotype of elevated BP and its response to riboflavin may be owing to 82 
perturbations in one-carbon metabolism in affected individuals; however, this mechanism has 83 
not been previously investigated. 84 
In one-carbon metabolism, FAD-dependent MTHFR generates 5-methyltetrahydrofolate (5-85 
MTHF), which is involved in the remethylation of hom cysteine to methionine, the pre-86 
cursor to S-adenosylmethionine (SAM; Figure 1). As the principal methyl donor, SAM 87 
transfers methyl groups to over 100 methyltransferas involved in numerous biochemical 88 
pathways including DNA methylation, histone modification and neurotransmitters [12]. This 89 
transfer, in turn, leads to the formation of S-adenosylhomocysteine (SAH), which is 90 
subsequently metabolised to homocysteine. DNA methylation, an epigenetic process 91 
involved in gene transcription and expression, has been implicated in a number of disease 92 
states across the life-cycle, including CVD [13]. The ratio of SAM:SAH has been sometimes 93 
used as a marker of methylation potential, although the validity of this indicator requires 94 
confirmation [14]. Choline and betaine can also serve as alternative methyl donors in 95 
homocysteine remethylation as part of the betaine-homocysteine methyltransferase (BHMT) 96 
pathway [15]. Homocysteine can be removed through irreversible condensation with serine to 97 
cystathionine via the action of cystathionine ß-synthase (CßS), in the pyridoxal-5′ phosphate 98 
(PLP)-dependent transsulfuration pathway. Regulation of the methylation cycle is essential to 99 
ensure sufficient supply of SAM to methyltransferas reactions. This is achieved through the 100 
action of SAM as an allosteric inhibitor of MTHFR and an allosteric activator of CßS, thus 101 
controlling one-carbon flux and homocysteine levels [16].  102 
Higher concentrations of  SAM and SAH have been report d in TT relative to CC adults in 103 
some [17,18] but not all [19,20] studies. In observational analysis of 10,601 Norwegian 104 
adults elevated homocysteine and decreased betaine were reported in TT compared to CC 105 
genotype groups, with no influence of genotype on other one-carbon metabolites [21–23]. 106 
Sub-optimal status of the B vitamins, folate, riboflavin, PLP and cobalamin, which act as 107 
nutritional cofactors for the key enzymes in the one-carbon pathway (Figure 2), have been 108 
previously shown to result in elevated homocysteine in adults generally and particularly by 109 
MTHFR genotype  [24,25]. The effect of intervention with one or a combination of these B 110 
vitamins has been shown to modulate homocysteine cocentrations [26–28]; however, the 111 
effect on other one-carbon metabolites has not beenwidely investigated, and few studies have 112 
considered the effect of the MTHFR 677TT genotype.  113 
Therefore, the aim of this study is to investigate th  impact of the MTHFR C677T 114 
polymorphism on one-carbon metabolite status and the responsiveness of one-carbon 115 
metabolites to riboflavin supplementation (1.6mg/day) in adults with the MTHFR 677TT 116 
genotype.  The findings of this study could contribute to our understanding of the mechanism 117 
underpinning the BP phenotype related to this gene-nutrient interaction.  118 
2.0 Materials and Methods 119 
2.1 Subjects and samples 120 
Plasma samples from participants who had previously participated in studies at the Nutrition 121 
Innovation Centre for Food and Health (NICHE), Ulster University, and had been screened for 122 
the MTHFR 677TT genotype were accessed for the current study. In all cases, participants 123 
provided informed, written consent and agreed for samples to be used in subsequent studies. 124 
Samples were accessed from the GENOVIT study (ORECNI ref 08/NIR03/40) [9], the 125 
GENOVIT follow-up study (ORECNI ref 08/NIR03/40) [10] and the RIBOGENE study 126 
(ORECNI/12/0338). Ethical approval for the analysis reported in the current study was granted 127 
by Ulster University Research Ethics Committee (FCBMS-18-040). All three studies had 128 
identical inclusion (pre-screened for MTHFR C677T polymorphism) and exclusion (history of 129 
gastrointestinal, hepatic or renal disease, consumers of B vitamin supplements, use of 130 
medication known to interfere with B vitamin metabolism) criteria. Clinic BP was measured in 131 
accordance with guidelines from the National Institute of Care and Excellence [29]. In brief, 132 
after ten minutes at rest, BP was measured in the reference arm, i.e. the arm with the highest 133 
BP, with the participant in the seated position. Mean BP was calculated as the average of two 134 
BP readings within 5mmHg, with a maximum of six readings obtained. Anthropometry, health 135 
and lifestyle information and blood samples were colle ted according to appropriate 136 
standardised operating procedures as part of each study, described in detail elsewhere [9,10].  137 
The analysis for the current study consisted of both an observational and an intervention phase. 138 
In the observational phase, participants with the TT genotype were age-matched with a similar 139 
number of individuals with the CC genotype and compared for general characteristics and one-140 
carbon metabolite biomarker status. In the intervention phase, biomarker status of methionine, 141 
SAM, SAH, SAM:SAH ratio, betaine, choline and cystathionine in response to intervention 142 
with riboflavin (n 24) and placebo (n 23) were investigated (Figure 2).  143 
2.2. Blood sampling 144 
Venipuncture of a vein in the antecubital fossa wasconducted by a trained phlebotomist with 145 
the participant in a non-fasting state. A 25ml blood sample was obtained into two EDTA 146 
vacutainers (9ml and 4ml) and two serum vacutainers (8ml and 4ml). All tubes, apart from the 147 
4ml EDTA tube, were placed immediately on ice and centrifuged at 3000 rpm for 15 minutes at 148 
4º Celsius, within 30 minutes of the venipuncture. Plasma, serum and buffy coat were removed 149 
at this stage. The erythrocytes in the 9ml EDTA tube were thrice washed with phosphate 150 
buffered saline and these washed red cells were used for erythrocyte glutathione reductase 151 
activation coefficient (EGRac) analysis. The 4ml EDTA tube was rolled for 30 minutes, and 152 
50µl was added to 450µl of 1% ascorbic acid solution (1 in 10 dilution), from which red blood 153 
cell folate was determined. All fractions were labelled and stored at -80º Celsius in alarm-154 
controlled freezers with batch analysis of biomarkers conducted at the end of the study. The 155 
samples did not undergo any freeze-thaw cycles between initial storage and analysis. 156 
2.3 B vitamin biomarker analysis  157 
Riboflavin status was determined at Ulster University using the erythrocyte glutathione 158 
reductase activation coefficient (EGRac) assay, which measures the enzyme activity of 159 
glutathione reductase before and after in vitro reactiv tion with its prosthetic group FAD, as 160 
described elsewhere [10]. EGRac is calculated as the ratio of FAD-stimulated to unstimulated 161 
enzyme activity, with values <1.3 indicating optimal riboflavin status, 1.3-1.4 suboptimal status 162 
and >1.4 signifying deficiency. Red blood cell folate concentrations, a long-term biomarker of 163 
folate status was measured by microbiological assay u ing Lactobacillus casei, as described by 164 
Molloy & Scott [30].  Plasma PLP, as a marker of vitamin B6 status, was analysed by HPLC 165 
[31]. Plasma homocysteine was analysed by fluorescence polarisation immunoassay for plasma 166 
homocysteine [32]. 167 
2.4 Metabolite analysis 168 
One-carbon metabolites, apart from homocysteine, were analysed at the Center of 169 
Metabolomics, Baylor Scott & White Research Institute (Dallas, Texas 75226). Determination 170 
of methionine, SAM, SAH, betaine, choline and cystathionine in plasma was performed by high 171 
performance liquid chromatography coupled with electrospray positive ionization tandem mass 172 
spectrometry (HPLC-ESI-MS/MS) using a method previously described with some minor 173 
modification [33]. In brief, 20µl of plasma was adde  to 180µl of isotope internal standards and 174 
loaded into a microtiter plate before being centrifuged for 60 minutes prior to analysis. The 175 
calibration curve for SAM and SAH was 25-400-nmol/L, for methionine, betaine and choline; 176 
3.1-50 nmol/L and for cystathionine: 125-2000 nmol/L.  Two levels of quality control samples 177 
were used to monitor within and between day precision of the method. In all cases, the 178 
coefficient of variation (cv) was less than 15% for all metabolites.  179 
2.5 Statistical analysis 180 
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS; 181 
version 25.0; SPSS UK Ltd, Chertsey, UK). Normality tests were carried out on the data and 182 
data not normally distributed were log transformed b fore analysis was conducted. Differences 183 
in general characteristics and one-carbon metabolite status between genotype groups 184 
(observational cohort) were determined using independent samples t-test. Chi square test was 185 
used for comparison between categorical variables. To determine the response to intervention, 186 
within-between repeated-measures ANCOVA was used, controlling for baseline EGRac. The 187 
between-participant factor was the intervention group (placebo compared with riboflavin), and 188 
the within-participant factor was time (before compared with after intervention). Results are 189 
presented as mean (SD), unless otherwise stated. P<0.05 was considered significant in all 190 
analysis carried out. Network analysis was performed with visualisation of the networks in a 191 
circular layout in corrplot and qgraph packages from R (version 3.3.0; R Core Team 2016, 192 
Vienna, Austria; www.R-project.org).  193 
3.0 Results 194 
Available plasma samples and data from adults (n 115) screened for the MTHFR genotype, and 195 
who previously participated in trials to lower BP were accessed. In the observational cohort, 196 
there were no significant differences in general characteristics between MTHFR genotype 197 
groups (Table 1). EGRac, the functional indicator of riboflavin status, was similar across the 198 
groups. PLP, serum and red blood cell folate concentrations were significantly lower in those 199 
with the TT compared to CC genotype. As previously reported, both systolic and diastolic BP 200 
were significantly elevated in the TT relative to CC genotype groups (mean difference 16.6 ± 201 
3.4 mmHg, P<0.001; 9.0 ± 13.5 mmHg, P<0.001, respectively), and those with the TT genotype 202 
were more likely to be classed as hypertensive according to current NICE guidelines [29]. 203 
There was no difference in use of anti-hypertensive medications between groups (75% of CC 204 
and 83% of TT genotype, P=0.308).  205 
In relation to one-carbon metabolites, elevated homocysteine (10.4 ± 3.0 vs 9.3 ± 2.5 µmol/L 206 
P=0.043), lower SAM concentrations (74.7 ± 21.0 vs 85.2 ± 22.6 nmol/L P=0.013) and lower 207 
SAM:SAH ratio (1.66 ± 0.55 vs 1.85 ± 0.51, P=0.043) was observed in the TT compared to the 208 
CC genotype (Table 2). No differences were observed for methionine, SAH, betaine, choline or 209 
cystathionine by genotype group. Network analysis showed that the nature and strength of 210 
interrelationships of metabolites and B vitamins within one-carbon metabolism were influenced 211 
by MTHFR genotype (Figure 3). 212 
Table 1 
Characteristics of participants by MTHFR genotype (observational cohort n 115) 
  MTHFR 677CC 
 (n 68) 
MTHFR 677TT 
 (n 47) 
P value1 
Age (years) 54.7 (6.0) 54.3 (6.0) 0.807 
Male sex n (%) 58 (85) 37 (79) 0.361 
BMI (kg/m2) 29.1 (4.9) 29.1 (4.6) 0.956 
Diabetes mellitus n (%) 8 (12) 5 (11) 0.851 
Smoker n (%) 16 (24) 17 (36) 0.141 
Family history CVD n (%) 31 (46) 34 (72) 0.229 
    
B vitamin biomarkers       
Red blood cell folate (nmol/L)     1055 (557) 809 (385) 0.045 
Serum folate (nmol/L) 12.2 (8.0) 6.7 (4.0) <0.001 
PLP (nmol/L) 72.0 (38.3) 47.5 (22.2) <0.001 
EGRac (riboflavin status) 1.37 (0.18) 1.36 (0.14) 0.788 
    
Blood Pressure     
Systolic BP (mmHg) 128.0 (16.6) 144.7 (19.2) <0.001 
Diastolic BP (mmHg) 78.8 (11.9) 87.1 (12.4) <0.001 
Pulse pressure (mmHg) 49.3 (12.4) 57.3 (16.6) 0.004 
Hypertensive2 n (%) 17 (25) 29 (62) <0.001 
BP medications n (%) 51 (75) 39 (83) 0.308 
Values are mean (SD). 1 P values refer to differences between genotype groups compared 
using independent samples t-test. Chi square test used for comparison between categorical 
variables. P<0.05 considered significant. 2Hypertension defined as a BP reading of 
≥140mmHg systolic and/or ≥90mmHg diastolic BP [31]. BP, blood pressure; CVD, 
cardiovascular disease; EGRac, erythrocyte glutathione reductase activation coefficient (a 
marker of riboflavin status where lower EGRac values indicate better riboflavin status); PLP, 





One-carbon metabolites by MTHFR genotype (observational cohort n 115) 





Homocysteine (µmol/L) 9.3 (2.5) 10.4 (3.0) 0.043 
Methionine (µmol/L) 29.5 (7.2) 30.3 (6.7) 0.450 
SAM (nmol/L) 85.2 (22.6) 74.7 (21.0) 0.013 
SAH (nmol/L) 45.0 (10.9) 46.8 (9.8) 0.320 
SAM:SAH ratio 1.85 (0.51) 1.66 (0.55) 0.043 
Betaine (µmol/L) 53.1 (13.7) 50.5 (15.8) 0.194 
Choline (µmol/L) 9.7 (2.1) 9.8 (2.7) 0.869 
Cystathionine (nmol/L) 243 (96) 248 (118) 0.965 
Values are mean (SD). 1Differences between genotype groups compared using independent t-
tests. SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine. P<0.05 considered 
significant.  
 
As previously reported [9–11], significant decreases were observed in both systolic (-14.0 ± 213 
15.3 mmHg, P=0.030) and diastolic BP (-8.2 ± 11.1 mmHg, P=0.013) in response to riboflavin 214 
supplementation which resulted in a significant decrease in EGRac (-0.15 ± 0.16, P<0.001), 215 
indicating improved riboflavin status, in those with the MTHFR 677TT genotype (Figure 4). 216 
No change in red blood cell folate was observed (data not shown).  217 
Response of one-carbon metabolites to riboflavin intervention among individuals with the TT 218 
genotype in MTHFR is presented in Table 3. Plasma homocysteine decreased by 0.5 ± 1.7 219 
µmol/L in the riboflavin group, albeit an effect tha  was non-significant compared to the 220 
placebo group. Mean plasma SAM concentration increased significantly in response to 221 
riboflavin supplementation by 19.5 ± 20.6 (P=0.021), where the nature of this effect was only 222 
strengthened when adjusted for baseline riboflavin status (P=0.008). Plasma cystathionine 223 
concentrations increased by 50.7 ± 92.5 nmol/L (P=0.021), in response to riboflavin 224 
supplementation. No other metabolites were affected by riboflavin intervention.  225 
Table 3  
One-carbon metabolite response to riboflavin intervention in adults with the MTHFR 677TT genotype (n 47)  
Values presented as mean (SD). 1 P value refers to time*treatment interaction (repeated measures ANOVA, comparing the effect of treatmen vs 
placebo over time). Model 1: unadjusted, Model 2: adjusted for baseline EGRac. P<0.05 considered significa t. SAM, S-adenosylmethionine; 









  Pre Post Pre Post Model 1 Model 2 
Homocysteine (µmol/L) 10.2 (3.4) 9.9 (3.4) 10.0 (2.4) 9.5 (2.0) 0.860 0.548 
Methionine (µmol/L) 29.4 (5.7) 29.5 (6.6) 30.5 (7.0) 33.8 (10.0) 0.213 0.310 
SAM (nmol/L) 74.4 (23.9) 74.3 (18.6) 72.3 (20.1) 91.8 (27.3) 0.021 0.008 
SAH (nmol/L) 42.9 (8.9) 36.9 (11.5) 48.1 (9.0) 43.3 (8.8) 0.287 0.295 
SAM:SAH ratio 1.73 (0.56) 1.96 (0.60) 1.58 (0.57) 2.14 (0.78) 0.192 0.182 
Betaine (µmol/L) 46.7 (16.1) 48.2 (15.9) 51.6 (15.5) 53.9 (18.0) 0.854 0.777 
Choline (µmol/L) 9.3 (2.7) 9.3 (2.5) 10.0 (2.61) 10.0 (2.9) 0.642 0.816 
Cystathionine (nmol/L) 206 (61) 196 (73) 215 (78) 266 (114) 0.021 0.045 
4.0 Discussion 226 
The findings of the current study report for the first time that that plasma concentrations of 227 
the one-carbon metabolites, SAM and cystathionine, i crease significantly in response to 228 
riboflavin supplementation in individuals with the MTHFR C677T polymorphism. Coincident 229 
with this finding, we also observed lower concentrations of plasma SAM in TT compared to 230 
CC genotype adults. Indeed, after intervention with riboflavin in adults with the TT genotype, 231 
SAM concentrations increased to levels similar to th se observed in adults with the CC 232 
genotype at baseline. The changes in plasma SAM and cystathionine concentrations in 233 
response to riboflavin intervention are consistent with the genotype specific BP response 234 
previously reported in response to supplementation with riboflavin, raising the possibility that 235 
the effect of this gene-nutrient interaction on BP may be influenced by the cofactor 236 
requirements.  237 
To our knowledge, this is the first study to investiga e the effect of intervention with 238 
riboflavin on SAM concentrations in adults with the MTHFR 677TT genotype. Previous 239 
investigations have, however, considered the effect of folic acid supplementation on one-240 
carbon metabolites.  In a small sub-group of MTHFR 677TT patients from the Verona Heart 241 
Study Project, 5mg/d folic acid resulted in significant increases in SAM by 13nmol/L and 242 
SAM:SAH ratio by 3.3, in addition to the expected reductions in homocysteine following 8 243 
weeks of treatment [35]. The extent of the response in SAM of almost 20 nmol/L bserved in 244 
the current study in response to riboflavin is even greater than these previous observations 245 
[35]. As the principal methyl donor, SAM-dependent methylation regulates fundamental 246 
biological processes including nuclear transcription, cell signalling, mRNA translation and 247 
DNA synthesis [12] and altered DNA methylation has previously been observed in TT 248 
relative to CC adults [36]. Supplementing with B vitamins to regulate concentrations of SAM 249 
in adults with perturbed one-carbon metabolism owing to genetic variants, could thus 250 
potentially have important implications for CVD health outcomes. Previous studies have 251 
linked methylation with hypertension; however, no one has considered the C677T 252 
polymorphism in MTHFR or its relationship with SAM or BP. This is the first study to show 253 
that riboflavin supplementation in those with the mutant genotype affects concentrations of 254 
SAM and thus, possibly methylation potential. A recent meta-analysis reported lower global 255 
methylation levels with higher systolic BP, diastolic BP and hypertension [37]. The same 256 
meta-analysis also reported lower methylation levels of a number of candidate genes with 257 
increased BP; however, MTHFR has not yet been considered to any great extent. While 258 
hypertension was not considered in a meta-analysis by Amenyah et al., lower global 259 
methylation was reported in those with the TT genotype in combination with low folate status 260 
[38]. 261 
Choline and 5-MTHF are considered fungible methyl group sources in one-carbon 262 
metabolism, and methyl groups from choline can alsofacilitate homocysteine remethylation 263 
via the BHMT pathway [15]. In a study of folate-deficient males with the TT genotype, 264 
intervention with 2,200 mg/day choline over 12 weeks was found to significantly increase 265 
plasma SAM concentrations compared to lower choline doses of 300-500 mg which were 266 
associated with a decreased SAM concentration [18].Whilst these studies investigated one-267 
carbon nutrients, BP was not considered. To date, research examining the effect of 268 
supplementation with B vitamins on one-carbon metabolites in adults with the MTHFR 269 
677TT genotype has predominantly focused on the establi hed phenotype of elevated 270 
homocysteine. Numerous meta-analyses demonstrating the responsiveness of homocysteine 271 
to supplementation with a combination of B vitamins have been published [24,25,39]; 272 
however, other one-carbon metabolites apart from hoocysteine have received little attention 273 
in studies of this nature. Studies at our Centre have previously reported that riboflavin 274 
supplementation lowers homocysteine in TT, but not CC, individuals, although, the response 275 
of other one-carbon metabolies were not considered [9,26]. 276 
Plasma cystathionine significantly increased in respon e to riboflavin supplementation in the 277 
current analysis. It is possible that increased avail bility of SAM, an allosteric regulator of 278 
cystathionine ß-synthase (CßS), in response to riboflavin may potentially have activated CßS, 279 
thereby increasing homocysteine elimination from the one-carbon pathway and generating 280 
cystathionine [16]. In addition, riboflavin administered at the same dose as the current study 281 
(1.6 mg/day) has previously been found to improve PLP status in older adults [40] and may 282 
thus augment the activity of PLP-dependent CßS. Consistent with earlier findings reported by 283 
Midttun and colleagues [23] lower PLP concentrations were observed in the current study in 284 
participants with the TT genotype. Those with the MTHFR 677TT genotype have reduced 285 
affinity for their riboflavin cofactor, FAD [6], thus are likely to have an increased 286 
requirement for riboflavin.  Considering that cells appear to have a tendency to spare FAD at 287 
the expense of FMN [41] it is possible that FMN-dependent pathways (such as the pathway 288 
required to convert vitamin B6 into active PLP) may be compromised in those with the 289 
mutant genotype, leading to reduced vitamin B6 metabolism and thus lower PLP 290 
concentrations. 291 
A paucity of evidence exists with respect to investigating the impact of MTHFR genotype on 292 
SAM and SAH concentrations. In a cohort of Mexican-American males, Shin et al., reported 293 
increased concentrations of SAH and decreased SAM:SH ratio in those with the TT 294 
compared to the CC genotype [18]. Davis et al., observed elevated SAM in young females 295 
with the TT relative to CC genotype; however this was not significant [17]. This is in contrast 296 
with the findings of the current analysis, where decreased SAM was observed in the TT 297 
compared to CC genotype group. Increased transmethylation reaction flux (i.e. conversion of 298 
SAM to SAH) has been found in females with the TT compared to the CC genotype [42]. A 299 
number of studies have found that the TT genotype is not a determinant of SAM or SAH 300 
[17,43] but folate status appears to be an important modulator of this effect [20]. Pertubations 301 
in one-carbon metabolism can impair the synthesis of SAM, and potentially lead to epigenetic 302 
alerations (specifically aberrant DNA methylation); correspondingly global DNA 303 
hypomethylation has been previously reported in indiv duals with the TT compared to CC 304 
genotype [44,45]. The ratio of SAM:SAH has been proposed by some as an indicator of 305 
methylation potential, although confirmation of its validity remains to be established. 306 
Methylation regulation enzymes are differentially expressed in human tissues, leading to 307 
tissue-specific SAM and SAH regulation and therefor methylation capacity. Thus systemic 308 
SAM:SAH ratio is not necessarily a meaningful indicator of methylation potential in all 309 
tissues [14]. In the current analysis, lower SAM:SAH ratio was observed in the TT compared 310 
to CC genotype group, driven by the reduced SAM concentrations. However, these results are 311 
at odds with another study that reported the MTHFR genotype did not influence the ratio of 312 
SAM:SAH [43]. 313 
The observational results of the current analysis are broadly in agreement with those of the 314 
Norwegian Colorectal Cancer Prevention (NORCCAP) study, where differences in one-315 
carbon metabolite status in individuals with the TT relative to the CC genotype were reported 316 
in 10,601 adults aged 50–64 years [21–23].  In agreement with our baseline analysis, these 317 
studies also reported the expected phenotype of elevat d homocysteine, lower folate and 318 
lower PLP concentrations in the TT compared to the CC genotype. No MTHFR genotype 319 
effect was noted in relation to methionine, choline a d cystathionine. One notable difference 320 
in the observed associations reported in the Norwegian cohort compared to the current cohort 321 
is betaine, where concentrations among Norwegians were significantly lower in those with 322 
the TT genotype compared to non-TT genotypes [22]. Betaine has been suggested as a 323 
preferential methyl donor in TT males relative to CC males [46]; however, in our analysis no 324 
genotype effect was noted with respect to betaine.  325 
4.1 Strengths and limitations  326 
This is the first study to consider the effect of the MTHFR cofactor, riboflavin, on one-carbon 327 
metabolites in adults stratified by MTHFR genotype. Samples from a number of carefully 328 
conducted randomised controlled trials utilising identical dose, duration and study protocols 329 
were accessed. The one-carbon metabolite analysis, which is known to pose analytical 330 
challenges, was conducted at a Centre with considerable expertise in laboratory analysis of 331 
one-carbon metabolite biomarkers. Furthermore, EGRac is considered the gold standard 332 
method for measurement of long-term riboflavin status and this measure was available for all 333 
participants. One limitation of the current study is the relatively small sample size which may 334 
have limited the ability to detect small differences in certain metabolites either between 335 
genotypes or in response to riboflavin. Additional biomarker information, in particular 5-336 
MTHF, which is generated by the MTHFR enzyme, might fur her add to our understanding 337 
of the role of this gene-nutrient interaction in BPregulation. The intervention could also be 338 
extended to those with MTHFR 677CC genotype.  339 
5.0 Conclusion 340 
In conclusion, this study shows evidence of perturbed one-carbon metabolism in individuals 341 
with the MTHFR C677T polymorphism, in particular reduced concentrations of the principal 342 
methyl donor, SAM. This study provides the first evidence that altered one-carbon flux may 343 
be alleviated through riboflavin supplementation in individuals with the C677T variant in 344 
MTHFR. The findings of this study may shed some light on he mechanism underpinning the 345 
elevated BP phenotype related to this gene-nutrient interaction, which, in turn could influence 346 
health outcomes in adult cohorts. Future studies investigating the effect of riboflavin and 347 
other B vitamins on one-carbon metabolite concentrations, are needed to further explore the 348 
potential mechanisms underlying the effect of this gene-nutrient interaction on BP among 349 
individuals with the MTHFR 677TT genotype. 350 
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Figure legends 
 
Figure 1. Overview of one-carbon metabolism. Abbreviations: BHMT, betaine-
homocysteine methyltransferase; CβS, cystathionine-β-synthase; CTH, cystathionine γ-lyase; 
DHFR, dihydrofolate reductase; dTMP, deoxythymidine monophosphate; dUMP, 
deoxyuridine monophosphate; FAD, flavin adenine dinucleotide; GNMT, glycine N-
methyltransferase; MAT, methionine adenosyltransferas ; MS, methionine synthase; MT, 
methyltransferases; MTHFR, methylenetetrahydrofolate reductase; MTHFD, 
methylenetetrahydrofolate dehydrogenase; SAHH, S-adenosyl homocysteine hydrolase; 
SHMT, serine hydroxymethyltransferase; TS, thymidylate synthase. Adapted from James et 
al. [47].  
 
Figure 2. Flow diagram of study population. 1CC (wild type) and TT (homozygous) 
genotypes for the MTHFR C677T polymorphism. 
 
Figure 3. Network analysis to show interrelationships within o e-carbon metabolism by 
MTHFR genotype group: CC, panel a; TT, panel b. Positive and inverse associations 
indicated by green and red edges, respectively. Strength of association indicated by edge 
thickness. Abbreviations: Smk, smoking; SBP, systolic blood pressure; BMI, body mass 
index; Met, methionine; HCY, homocysteine; Cys, cystathionine; SAM, S-
adenosylmethionine; SAH, S-adenosylhomocysteine; SSr, AM:SAH ratio; Cho, choline; 
Bet, betaine; B2, riboflavin; PLP, Pyridoxal-5’-phosphate; RCF, red blood cell folate. 
 
Figure 4. Change in riboflavin biomarker (panel a), systolic BP (panel b), and diastolic BP 
(panel c) in response to supplementation with placebo or riboflavin (1.6mg/d) for 16 weeks. 
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